Telix Adds Lead-212 Isotope Production Capability
Telix today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first…
Read more
Leading a new era in radiopharmaceuticals
Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.
Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is underpinned by a strong global supply, manufacturing and distribution network.
Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 18 clinical trials underway worldwide.